Denali Therapeutics Inc. DNLI Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$128.45M+0.1% | -$128.55M-1.3% | -$126.9M-2.2% | -$124.12M+6.7% | -$132.97M-15.9% | ||
| $2.85M-0.7% | $2.87M-2.7% | $2.95M-3.2% | $3.05M+31.0% | $2.33M+25.5% | ||
| $23.09M-3.6% | $23.95M-4.7% | $25.14M-1.0% | $25.39M+0.9% | $25.16M+0.3% | ||
| $3.88M+214% | -$3.41M+16.2% | -$4.07M— | —— | -$2.64M-305% | ||
| -$22.4M-276% | $12.73M+574% | $1.89M+142% | -$4.47M+53.9% | -$9.69M— | ||
| $700K— | —— | —— | -$3.97M-520% | $943K+153% | ||
| -$294K— | —— | —— | —— | $0— | ||
| -$131.2M-33.2% | -$98.54M+8.2% | -$107.3M-42.5% | -$75.3M+42.7% | -$131.47M-57.0% | ||
| $2.47M+61.8% | $1.52M— | —— | $4.28M-15.8% | $5.08M-0.3% | ||
| $94.46M+355% | $20.77M-64.1% | $57.83M-63.4% | $157.94M+742% | $18.75M— | ||
| $12.37M+46.2% | $8.46M— | $0— | $0— | $0+100% | ||
| $17K+6.3% | $16K-98.8% | $1.36M-44.1% | $2.43M-44.1% | $4.36M-47.7% | ||
| —— | $81K0.0% | $81K0.0% | $81K0.0% | $81K— | ||
| $219.04M+14.0% | $192.13M+24,796% | -$778K-148% | $1.62M+143% | -$3.76M— | ||
| $182.3M+59.4% | $114.36M+328% | -$50.24M-160% | $84.26M+172% | -$116.48M-238% | ||
| -$22.4M-276% | $12.73M+574% | $1.89M+142% | -$4.47M+53.9% | -$9.69M— | ||
| -$5.99M— | —— | —— | —— | $19.94M+95.8% | ||
| $1.14M-0.1% | $1.15M+0.1% | $1.14M+2.9% | $1.11M+6.0% | $1.05M0.0% | ||
| $2.29M— | —— | —— | —— | $28.61M— | ||
| $1.26M-23.3% | $1.64M-19.0% | $2.03M-24.9% | $2.7M-30.6% | $3.89M-36.9% | ||
| -$294K— | —— | —— | —— | $0— | ||
| $17K+6.3% | $16K-98.8% | $1.36M-44.1% | $2.43M-44.1% | $4.36M-47.7% | ||
| $6.7M+108% | $3.22M+453% | $583K-85.6% | $4.06M+582% | $595K-85.7% | ||
| $916K0.0% | $916K+1.8% | $900K0.0% | $900K+1.5% | $887K+15.8% | ||
| $36M— | —— | —— | —— | $0— | ||
| $200M— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$133.67M-33.6% | -$100.06M+5.5% | -$105.92M-33.1% | -$79.58M+41.7% | -$136.55M-53.8% | ||
| -$133.67M-33.6% | -$100.06M+5.5% | -$105.92M-33.1% | -$79.58M+41.7% | -$136.55M-53.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Denali Therapeutics Inc.'s cash flow data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.